

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	10/087,987
Filing Date	03/05/2002
First Named Inventor	ROBERT B DICKSON
Art Unit	1642
Examiner Name	Susan UNGAR
Attorney Docket Number	082137-0280712

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LONG ET AL., "Synthesis and evaluation o the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase," Bioorg. Med. Chem. Lett., Abstract, p. 2515-9, (September 17, 2001).	
		YAMASAKI ET AL., "Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors," J. Ntru.. Sci. Vitaminol., Abstract, Vol. 49 (No. 1), p. 27-32, (February 5, 2003).	
		STTOP ET AL., "Engineering of a macromolecular scaffold to develop specific protease inhibitors," Nat. Biotechnol., Vol. 21 (No. 9), p. 1603-8, (September 5, 2003).	
		FORBS ET AL., "In vitro inhibition of matriptase preents invasive growth of cell lines of prostate and colon carcinoma," Int. J. Oncol., Vol. 27 (No. 4), p. 1061-70, (October 5, 2005).	
		DESILETS ET AL., "Inhibition of human natriptase by eglin c variants," FEBS Lett., Vol. 580 (No. 9), p. 2227-32, (April 17, 2006).	
		GALKIN ET AL., "CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts," Vol. 61 (No. 3), p. 228-35, (November 1, 2004).	
		FOLTZ ET AL., "Generation of a Fully Human High Affinity Neutrilizing Antibody Against MT-SPI/Matriptase and Its Potential Role for the Treatment of B Cell Lymphoma," Blood, Abstract, (June 5, 2005).	
		JANC ET AL., "A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivity are dramatically enhanced by Zinc (II)," Biochemistry, Abstract, Vol. 39 (No. 16), p. 4792-800, (April 25, 2000).	
		KATZ ET AL., "Design of potent selective zinc-mediated serine protease inhibitors," Nature, Abstract, p. 608-12, (February 5, 1998).	
		LIST ET AL., "Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation," Genes & Development, Cold Spring Harbor Laboratory Press, p. 1934-50, (January 24, 2005).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14436/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet#

2

of

2

Complete If Known

Application Number

10/087.987

Filing Date

03/05/2002

First Named inventor

ROBERT B. DICKSON

Art Unit

1642

Examiner Name _____

Susan UNGAR

Attorney Docket Number

082137-0280712

NDN PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[†]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[‡]
	See Attachment 1	KANG ET AL., "Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator 1 in the Progression of Node-negative Breast Cancer," <i>Cancer Research</i> , p. 1101-05, (March 1, 2003). Enyedy et al, "Structure-based approach for the discovery of bis-benzamides as novel inhibitors of matriptase; J. Med. Chem. pp. 1349-55 (Abstract) April 26, 2001	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation (user optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Addendum

Attachment 1

- a.
- b. SUZUKI ET AL., "Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase," J. of Biol. Chem., The American Society for Biochemistry and Molecular Biology, Inc., Vol. 279 (No. 15), p. 14899-908, (April 9, 2004).
- c.